Added to YB: 2026-09-17
Pitch date: 2026-09-15
DARE [neutral]
Daré Bioscience, Inc.
Author Info
No bio for this author
Company Info
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Market Cap
$11.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.66
P/E
-0.95
EV/Sales
3.96
Sector
Pharmaceuticals
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 2: Daré Bioscience, Inc.
DARE (quick overview): Daré Bioscience is a $0.70 women’s-health commercial-transition and clinical-catalyst story. FloraSync is launched and DARE to PLAY should begin dispensing in 3Q26, but paid prescriptions, repeat purchases and customer-acquisition economics remain unproven. Ovaprene is the principal value driver, with Phase 3 topline data targeted for 2027; Phase 2 DARE-HPV data provide the main secondary upside.
Read full article (2 min)